Frequently asked questions about Gavi's revised co-financing, prepared by the Gavi Secretariat in June 2012.
Co-financing is a term used by Gavi to signify that countries share a portion of the cost of their
new vaccines and safe injection devices. Co-financing is actually
co-procurement of Gavi-supported vaccines and safe injection devices by
Countries are asked to start co-financing
as soon as they introduce new Gavi-supported vaccines and, depending on
their level of GNI per capita, to make gradually increasing
contributions. The objective is to put countries on a trajectory towards
financial sustainability in order to prepare them for phasing out of Gavi support for new vaccines.
The timeframe for attaining financial
sustainability will vary across countries. For the poorest countries,
many years may be required to achieve financial sustainability, and
therefore an intermediate objective is to gradually enhance country
contribution and ownership of vaccine financing.
The vaccines exempt from co-financing are measles second dose and
preventive campaigns with measles-rubella, Meningococcal A and Yellow